|
|
|
|
|
Quarterly Performance
|
Qtr Ended |
Revenues |
Net Income |
EPS |
| 03 / 2002
|
1691 |
-2317 |
-1.9299999999999999378275106209912337362766265869140625 |
| 06 / 2002
|
1703 |
-2580 |
-2.04999999999999982236431605997495353221893310546875 |
| 09 / 2002
|
1756 |
-2096 |
-1.62999999999999989341858963598497211933135986328125 |
| 12 / 2002
|
2200 |
-1604 |
-1.2399999999999999911182158029987476766109466552734375 |
| 03 / 2003
|
1924 |
-2680 |
-1.939999999999999946709294817992486059665679931640625 |
| 06 / 2003
|
1338 |
-3573 |
-2.54999999999999982236431605997495353221893310546875 |
| 09 / 2003
|
1311 |
-3541 |
-2.529999999999999804600747665972448885440826416015625 |
| 12 / 2003
|
604 |
3152 |
0.190000000000000002220446049250313080847263336181640625 |
|
|
|
|
Major Stock Holders
(Prior To
Offering) |
Name |
Class A |
|
Abbott Laboratories |
NA |
10.10 |
NA |
NA |
NA |
NA |
|
Alta BioPharma Partners, L.P. |
NA |
13.10 |
NA |
NA |
NA |
NA |
|
HBM BioVentures (Cayman) Ltd. |
NA |
7.40 |
NA |
NA |
NA |
NA |
|
J.P. Morgan Partners (SBIC), LLC |
NA |
8.10 |
NA |
NA |
NA |
NA |
|
Venrock Associates II, L.P. |
NA |
10.40 |
NA |
NA |
NA |
NA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income Data |
| Year |
Revenues |
Costs |
Oper Income |
Taxes |
Net Income |
EPS |
| 2001
|
6441 |
17302 |
-10861 |
0.00 |
-9361 |
-9.9000000000000003552713678800500929355621337890625 |
| 2002
|
7350 |
16254 |
-8904 |
0.00 |
-8597 |
-6.82000000000000028421709430404007434844970703125 |
| 2003
|
5177 |
19585 |
-14408 |
0.00 |
-14361 |
-4.75 |
|
|
|
Balance Sheet Data
|
Year |
Cash |
Acct Recv. |
Inventory |
Total Cur Assets |
Total Cur Liability |
PPE |
Total Assets |
LT Debt |
SH Equity |
|
2002 |
26561 |
84 |
0.00 |
27461 |
3407 |
2585 |
30923 |
0.00 |
26429 |
|
2003 |
32434 |
66 |
0.00 |
33772 |
3910 |
2137 |
36647 |
0.00 |
31812 |
|
|
|
| Cash
Flow Summary
|
Year |
Net Cash-Ops |
Net Cash-Inv |
Net Cash-Fin |
Net Change |
|
2001 |
-7918 |
14224 |
6874 |
13180 |
|
2002 |
-7691 |
1102 |
783 |
-5806 |
|
2003 |
-12772 |
-776 |
19421 |
5873 |
|
|
| |
|
| |